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There is general agreement in the scientific community on the need to improve carcinogenicity
testing and the assessment of human carcinogenic risk and to incorporate more information on
mechanisms and modes of action into the risk assessment process. Advances in molecular
biology have identified a growing number of genes such as protooncogenes and tumor-
suppressor genes that are highly conserved across species and are assocjated with a wide
variety of human and animal cancers. In vivo transgenic rodent models incorporating such
mechanisms are used to identify mechanisms involved in tumor formation and as selective tests
for carcinogens. Transgenic methods can be considered an extension of genetic manipulation by
selective breeding, which long has been employed in science and agriculture. The use of two
rodent species in carcinogenicity testing is especially important for identifying transspecies
carcinogens. The capacity of a substance to induce neoplasia across species suggests that the
mechanism(s) involved in the induction of the neoplasia are conserved and therefore may have
significance for humans. Based on available information there is sufficient experience with some
in vivo transgenic rodent carcinogenicity models to support their application as complementary
second species studies in conjunction with a single 2-year rodent carcinogenicity study. The
optional substitution of a second 2-year rodent carcinogenicity study with an alternative study
such as an in vivo transgenic carcinogenicity study is part of the International Conference on
Harmonization guidance Si B: Testing for Carcinogenicity of Pharmaceuticals. This guidance is
intended to be flexible enough to accommodate a wide range of possible carcinogenicity
assessment models currently under consideration or models that may be developed in the future.
The use of an in vivo transgenic mouse model in place of a second 2-year mouse study will
improve the assessment of carcinogenic risk by contributing insights into the mechanisms of
tumorigenesis and potential human relevance not available from a standard 2-year bioassay. It is
envisioned that this will stimulate the further development of more efficient and relevant
methods for identifying and assessing potential human carcinogenic risk, which will benefit public
health. Environ Health Perspect 106(Suppl 1):71-80 (1998). http.//ehpnet1.niehs.nih.gov/
docs/1998/Suppl-1/71-80contrera/abstract.html
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Introduction
Application of new approaches for regulatory agencies in part because ofthe
assessment ofthe carcinogenic potential of complexity of the carcinogenic process.
pharmaceuticals such as in vivo transgenic Cancer is a multistage process associated
rodent models is a major challenge for with changes in the integrity or expression
the scientific community, industry, and of genomic DNA (1-5). Advances in
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molecular biology have identified a growing
number of genes associated with cancer
that include those operationally classified
as protooncogenes and tumor-suppressor
genes. Many ofthese genes are highly con-
served across species and are associated
with a wide variety ofhuman and animal
cancers including cancer ofthe colon, lung,
breast, esophagus, stomach, skin, prostate,
and the hematopoietic and central nervous
systems (6-13).
Transgenic rodents have yielded impor-
tant new insights into carcinogenic mecha-
nisms and some transgenic models also
have potential application for identifying
carcinogens (14,15). Transgenic methods
can be considered an extension ofgenetic
manipulation by selective breeding that
long has been employed in science and
agriculture to produce animals with desired
phenotypic characteristics and relatively
uniform genotype. Transgenic animals use-
ful as cancer models have been developed
that contain regulated transgenes, unex-
pressed reporter genes, or knocked-out alle-
les oftumor-suppressor genes. Information
derived from in vivo transgenic carcino-
genicity models can contribute additional
insights (16,17) into the mechanism ofcar-
cinogenesis and possible human risk that
may be ofgreater value and potential rele-
vance to humans than information from a
second conventional 2-year rodent study.
Transgenic rodent models incorporating
appropriate human protooncogenes or
altered tumor-suppressor genes may be bet-
ter animal surrogates for human cancer
assessment than wild-type rodents currently
used in carcinogenicity studies.
Application of new approaches such as
transgenic rodent carcinogenicity models
should advance toxicology and regulatory
science and ultimately benefit public health
by applying more efficient and more rele-
vant methods for evaluating potential
human carcinogenic risk. Promising trans-
genic rodent carcinogenicity models are
currently being extensively characterized
and many more will undoubtedly be devel-
oped in the future. Regulatory authorities
can play an important role in fostering this
process by demonstrating a willingness to
apply new scientifically acceptable meth-
ods through more flexible policies that
accommodate improved, innovative
approaches for assessing potential human
carcinogenic risk.
For human pharmaceuticals, clinical
considerations determine the need for
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carcinogenicity studies and influence the
benefit-risk assessment. Clinical consider-
ations include the expected duration of
treatment, severity ofthe disease or disor-
der, nature ofthe patient population (e.g.,
children, elderly), extent ofhuman expo-
sure, the availability of other therapies,
and toxicity profiles of other available
therapies. A weight-of-evidence approach
is used to assess the potential carcino-
genicity ofhuman pharmaceuticals. This
approach includes the evaluation of
human and animal metabolic and pharma-
cokinetic data. The availability ofhuman
systemic exposure and metabolism data
from clinical trials and the controlled
medical use ofhuman prescription drugs
are advantages that often are not readily
available for evaluating potential human
risk in other regulatory areas (e.g., envi-
ronmental or industrial chemicals). This
information is used to assess the adequacy
of the rodent models for extrapolation to
humans and for estimating the relevant
human risk ofpharmaceuticals.
Principal Elements ofthe
Weight-of-evidence
Assessment of
Carcinogenic Potential
Evaluation ofthe results ofcarcinogenicity
studies (including alternative models) and
genotoxicity studies include:
* Magnitude ofcompound-related tumor
findings compared to those for the con-
current control
* Evidence ofcompound-related tumors
in two species (transspecies effect)
* Evidence oftumors at multiple sites
* Evidence oftumors in males and females
* Evidence ofa compound-related increase
in rare tumors
* Evidence ofan increased incidence of
compound-related fatal tumors and/or
tumors with short latencies (appearing
before terminal sacrifice)
* Evidence ofdose-related tumorfindings.
* Evidence ofa significant increase in the
incidence ofa tumor or tumors that are
histopathologically analogous to human
tumors
* Evidence oftumors at common sites in
two species
* Evidence suggesting that carcinogenic
response elements in the test species are
similar to those known to be involved in
human cancer (common mechanism)
* Evidence ofgenotoxicity
* Relative significance ofcarcinogenicity
findings in the contextofhistorical data
Examples of assessment factors in the
consideration of the adequacy of the test
model include:
* Adequacy ofdoses used and suitability
ofthe route ofadministration
* Bioavailability ofthe test compound in
the rodent test models
* Pharmacokinetic profile ofthe test com-
pound in rodent models and humans
* Metabolic profile ofthe test compound
in rodent test models and humans
* Pharmacodynamic comparability ofthe
test model to humans
* Appropriate application ofInternational
Conference on Harmonization (ICH)
guidances
Risk-benefit considerations include:
* Comparison of the clinical systemic
exposure at the estimated maximum
daily recommended dose to the systemic
exposure in the rodent test models
* If systemic exposure information is
lacking, the estimated exposure ratio
should be based on the surface area
(mg/im2) estimation ofdose in the test
species and the clinical maximum daily
recommended dose
* Severity ofthe disease or disorder and
the availability and relative efficacy of
alternative therapies
* Toxicity profile ofavailable alternative
therapies
* Size and composition of the patient
population and the frequency and
extent ofexposure
Utility ofTwo Rodent
Species in the Assessment
ofCarcinogenic Potential
The rodent carcinogenicity databases for
pharmaceuticals from the United States, the
European Union, and Japan were evaluated
by the ICH safety expert working group to
assess the utility oftwo rodent species for
carcinogenicity testing. This analysis sup-
ported a more flexible approach to the cur-
rent practice of2-year carcinogenicitystudies
in two rodent species. The U.S. Food and
Drug Administration (U.S. FDA) carcino-
genicity study database used in this analysis
contained 282 pharmaceuticals, with car-
cinogenicity studies in both rats and mice
(18). There is a significant (74%) concor-
dance in the results ofrat and mouse car-
cinogenicity studies in the U.S. FDA
database and 78% ofall compounds with
positive tumor findings were identified in a
single rat study (rat positive predictivity).
This is in accordwith the results ofthe data-
bases of the other ICH regions and the
rodent carcinogenicity database of U.S.
National Toxicology Program (U.S. NTP)
(19,20) and with the Carcinogenic Potency
Database (CPD) (21-23). Mouse carcino-
genicitystudies have arelativelylower overall
positive predictivity than rat studies, identi-
fying only 64% ofall compounds with posi-
tive tumor findings. For compounds that
produced tumors only in mice, 71% were
single-site tumors. Of the compounds
thatproduced tumors onlyin rats, 78% were
single-site tumors.
In considering the contribution ofthe
second rodent species carcinogenicity
study, it was recognized that identifying
compounds with transspecies tumorigenic
effects is an important component ofthe
weight of evidence for assessing human
carcinogenic potential. Compounds that
produce transspecies tumors are considered
to pose a relatively higher risk to humans
than single-species positive compounds
(24,25). It is postulated that the capacity
of a drug to induce a similar neoplasia
across species suggests that the mecha-
nism(s) involved in the induction of the
neoplasia are conserved and therefore may
have significance for humans. Thus, com-
pounds that produce transspecies tumors
generally are considered potentially more
hazardous than compounds with single-
species, single-site tumor findings. There
are, however, circumstances for which sin-
gle-species findings can have regulatory
implications. The strength ofthe finding,
nature of the tumor findings (e.g., rare
tumors, especially those histologically simi-
lar to human tumors), evidence ofgenotox-
icity, and the degree ofsimilarity in drug
metabolism and pharmacokinetics com-
pared to these findings for humans all con-
tribute to the weight-of-evidence approach
used to assess the potential human carcino-
genic risk. The severity and morbidity asso-
ciated with the clinical indication and the
availability and toxicity ofalternative thera-
pies are also important considerations that
influence theoverall assessment ofacceptable
risk forhuman pharmaceuticals.
A major regulatory concern in relying
on the results of a single carcinogenicity
study in a rodent species is that although
all transspecies carcinogens would be
detected using a single-species study, it
would be impossible to identify trans-
species carcinogens. In the U.S. FDA data-
base (18) 52 of 125 drugs (42%) with
tumor findings are transspecies positive.
Within this group there is a relatively high
proportion of unmarketed drugs, older
drugs, and drugs marketed with restricted
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clinical use related to carcinogenicity find-
ings. Transspecies rodent tumor findings
also have contributed significantly to regu-
latory decisions that prevented the market-
ing of drugs or resulted in the removal of
drugs from the market.
Single-rodent species tumor findings
can also influence the weight ofevidence in
the assessment of potential cancer risk.
Benzene is carcinogenic in the mouse but
not the rat and there is sufficient evidence
in humans to consider it a human carcino-
gen. Methapyrilene, an antihistamine, was
removed from the market in the United
States primarily because ofhepatocarcino-
genicity with short latency in rats (26).
The International Agency for Research on
Cancer (IARC) classified the tranquilizer
oxazepam as a possible human carcinogen
(IARC classification 2B) mainly on the
strength ofmouse liver findings (27).
Site concordance is not as important as
might be anticipated for pharmaceuticals
except, for example, when specific receptor-
mediated mechanisms ofcarcinogenesis are
implicated. The tumor site concordance of
rats and mice is relatively poor. In the U.S.
FDA, U.S. NTP, and CPD databases only
22, 26, and 33%, respectively, ofall com-
pounds with positive findings produced
tumor findings in at least one common site
in the rat and mouse (18,19,22). The lack
ofsite specificity has been cited as part of
the rationale for a reduced 2-year study
protocol using only male rats and female
mice (28,29). Iftumor site cannot be reli-
ably predicted between rodent species,
extrapolation of rodent tumor sites to
humans is also questionable (30). There
appears to be better transspecies tumor-site
concordance across species for a relatively
small select subset ofIARC 1, 2A, and 2B
classified pharmaceuticals (31). This appar-
ent concordance may be related to the
genotoxic nature ofa majority ofthe non-
hormonal compounds in this group (32);
even here concordance is not absolute.
Elimination of the second rodent
species carcinogenicity study would signifi-
cantly reduce the evidence available for reg-
ulatory decisions regarding potential
carcinogenic risk and would not improve
the assessment ofpotential human carcino-
genic risk or advance the state ofregulatory
science. In the absence ofa second species
study, regulatory decisions would by neces-
sity be based solely on the results ofa con-
ventional 2-year carcinogenicity study in
one species, with important regulatory con-
sequences. In this situation more reliance
would be placed on positive tumor findings
in a single study. In the absence ofinfor-
mation to the contrary, these findings
could effectively be regarded as equivalent
to positive findings in two rodent species.
Use ofan in Vivo
Transgenic Rodent Model
in Place of a Second 2-Year
Rodent Carcinogenicity Study
A variety ofcarcinogenic agents may exert
their effects by a common mechanism such
as the activation ofprotooncogenes or inac-
tivation oftumor-suppressor genes. In vivo
transgenic rodent carcinogenicity models
can be used to identify mechanisms
involved in tumor formation and as selec-
tive tests for carcinogens (33). The optional
substitution ofa second 2-year rodent car-
cinogenicity study with an alternative study
such as an in vivotransgenic carcinogenicity
study is an approach that would contribute
new insights into the mechanisms of
tumorigenesis and potential human rele-
vance. This option is part ofthe ICH guid-
ance SIB: Testingfor Carcinogenicity of
Pharmaceuticals (34), which is intended to
be flexible enough to accommodate a wide
range ofpossible carcinogenicity assessment
models that may be developed in the future
as well as to address test models currently
under consideration. Test models noted in
the ICH guidance currently under consid-
eration include initiation-promotion mod-
els, the neonatal mouse tumorigenicity
assay, and in vivotransgenic rodent models.
In the ICH guidance it is proposed that a
single 2-year carcinogenicity study be car-
ried out in the rodent species that best
models human metabolic, pharmacokinetic,
and pharmacodynamic parameters. Ifthe
rat and mouse appear equivalent in these
respects, the rat likely would be considered
the standard rodent model because ofthe
greater amounts ofinformation generally
available from supporting pharmacology
and toxicology studies carried out during
drugdevelopment.
There is general agreement in the scien-
tific community on the need to improve
assessment ofcarcinogenic risk and incor-
porate more information on mechanisms
and mode ofaction into the risk-assessment
process. These views were expressed by the
U.S. NTP Board ofScientific Counselors
(35) and IARC (36). Principles for the
application ofmechanisms ofcarcinogene-
sis in risk assessment were presented by
IARC and include evidence ofgenotoxic-
ity, i.e., structural changes at the gene level
and evidence ofeffects on the expression of
relevant genes, which would include alter-
ations in the structure or quantity of the
product of a protooncogene or tumor-
suppressor gene. Evidence that similar
mechanisms are acting in humans is consid-
ered important in evaluating the relevance
ofanimal findings. For these reasons, posi-
tive findings in transgenic models could
contribute more to the weight-of-evidence
assessment than equivocal tumor findings
in a second standard 2-year rodentstudy.
Transgenic models have been developed
that contain regulated transgenes, unex-
pressed reportergenes, orknocked-outalleles
oftumor-suppressor genes. Because ofthe
relative specificity of transgenic carcino-
genicity models or other factors that may
influence assay sensitivity (e.g., treatment
schedule, route ofadministration, differ-
ences in metabolism, and systemic expo-
sure), negative findings in asingle transgenic
model do not rule out carcinogenic poten-
tial in the rodent. Theymay, however, elim-
inate some possible mechanisms oftumor
formation. Similarly, in a standard 2-year
rodent study a negative response in one
strain ofmice does not necessarily rule out
the possibility ofa significant positive find-
ing in another mouse strain or in the rat.
The significance ofnegative findings in any
in vivocarcinogenicity bioassay is also influ-
enced by the toxicity ofthe test compound
relative to the minimal carcinogenic dose.
For toxic compounds the maximum toler-
ated dose for a 2-year study could be less
than the dose necessary to produce a signifi-
cant tumor response and could also result in
a lower systemic exposure than that attained
in humans at the maximum therapeutic
dose (37). The shorter duration ofexposure
to test compounds for alternative carcino-
genicity models (e.g., 26 weeks for trans-
genic models) may allow test animals to
tolerate relatively higher exposures to toxic
compounds than would be feasible in a
2-yearcarcinogenicity study.
Regulatory Application
ofTransgenic Mouse Models
Although not all of the mechanisms
involved in the induction of cancer are
known, there is a large and growing body
of evidence on the critical role tumor-
suppressor genes and protooncogenes play
in the induction ofcancer in animals and
humans (38-40). Thep53gene is an exam-
ple ofa major tumor-suppressor gene that is
highly conserved across species and is
involved in a high proportion of human
cancers (41,42). The p53 gene product is
involved in regulation ofthe fundamental
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processes ofapoptosis and DNA repair,
which playimportant roles in cancer forma-
tion (43,44). Humans with Li Fraumeni
syndrome are at greater risk of cancer
because ofa deficient p53 allele (45), and
aflatoxin-induced hepatocarcinogenesis in
humans has been associated with p53 and
rasoncogene mutations (46).
Transgenic mice that aredeficient in one
or both p53 gene alleles have been devel-
oped. Heterozygousp53-deficient mice have
accelerated tumor responses andlowsponta-
neous tumor rates over a large portion of
their lifespan, which allows the use of a
smaller number ofanimals (15-20/group vs
50 or more/group) and shorter treatment
periods (24 vs 104 weeks) than a standard
2-year mouse carcinogenicity study. In con-
trast to heterozygous p53-deficient mice,
homozygous mice have relatively short life-
spans and a high spontaneous incidence of
lymphoma and leukemia, which makes
them less desirable test models for car-
cinogenicity. The p53-deficient mouse is
particularly sensitive to genotoxic carcino-
gens (47). An operational definition of
genotoxicity is applied for pharmaceuticals
in which a compound that is positive in one
or more of the standard genotoxicity test
batteries may be considered genotoxic. The
standard genotoxicity test battery for phar-
maceuticals includes a test for bacterial
mutation, a test for chromosomal damage in
mammalian cells, and an in vivo test for
chromosomal damage in rodent bone mar-
row [ICH guidance S2A and S2B, available
on the internet (34)]. Although pharmaceu-
ticals are screened for genotoxicity and
strongly positive compounds generally are
eliminated early in drug development, com-
pounds often are developed that have weak
or equivocal results in one or more geno-
toxicity tests that comprise the standard test
battery or in genotoxicity tests that are not
part of the battery. These compounds
would be especially suited for testing in car-
cinogenicity assays responsive to genotoxic
compounds such as thep53-deficient het-
erozygous mouse. A critical question
addressed by this approach is the possible
relevance ofany genotoxicity findings to
any carcinogenic response.
In studies with compounds tested in
2-year mouse studies and thep53-deficient
mouse, there is evidence that the tumor
site in p53-deficient heterozygous mice
was also found in the 2-year mouse study,
although not all sites found in the 2-year
studies were represented in transgenic
studies (15,47). Information derived from
transgenic or other alternative models can
also be used to elucidate the significance of
tumors in a standard 2-year mouse study.
Some potential applications of an
alternative test method for carcinogenicity
follow:
* As an alternative to a second 2-year
rodent carcinogenicity study for
pharmaceuticals
* As a complementary confirmatory
study for drugs with equivocal car-
cinogenicity findings in 2-year rodent
studies when such findings would
adversely influence risk-benefit
considerations
* As a preliminary carcinogenic screen to
set priorities for full carcinogenicity
testing (e.g., retrospective testing
ofproducts approved before rodent car-
cinogenicity studies were routinely
required)
* As an alternative to repeating a 2-year
rodent carcinogenicity study. A 2-year
rodent study may not be adequate for a
variety of reasons such as inadequate
test animal survival, inappropriate dos-
ing or route ofadministration, or other
factors related to a change in clinical
indication orhuman exposure
* To assess the carcinogenic potential of
genotoxic contaminants or degradants
that were not present in a drug product
when evaluated in 2-year rodent
carcinogenicity studies
For example, phenolphthalein was
positive in a U.S. NTP 2-year rat and
mouse carcinogenicity study; it produced
thymic lymphoma, histiocytic sarcoma, and
ovarian tumors in the mouse and renal and
adrenal tumors in the rat (48). There was
also some evidence ofgenotoxicity from
studies including those not generallyconsid-
ered part ofthe standard genotoxicity bat-
tery oftests for pharmaceuticals. Concern
for the carcinogenic potential ofphenolph-
thalein was based largely on the mouse
hematopoietic tumor findings. To gain fur-
ther insight into these findings and their
potential human significance, the U.S. FDA
tested phenolphthalein in thep53-deficient
heterozygous mouse in addition to the fur-
ther studies of the pharmacokinetics and
comparative metabolism ofphenolphthalein
in relation to humans. Phenolphthalein pro-
duced dose-related thymic lymphomas in
thep53-deficient heterozygous mouse simi-
lar towhatwas observed in B6C3F1 mice in
the 2-year study and at similar doses (49).
The thymic tumors ofphenophlthalein-
treated p53-deficient mice were analyzed
and found to have lost their wild-typep53
allele (loss of heterozygosity). Thymic
lymphoma tumor tissues from the 2-year
mouse study were subsequently analyzed
for alterations in the level of p53 protein
and there was evidence of a increase in
nuclear p53 protein (49). The latter finding
was considered further confirmation ofa
treatment-related effect. Alterations in the
level ofp53 protein have been observed in
human tumors such as adenocarcinoma of
the pancreas (50). The results from the
phenolphthalein p53-deficient transgenic
mouse study and the known shared tumor-
suppressor function of the p53 gene in
rodents and humans contributed informa-
tion for the weight-of-evidence assessment
of the potential human relevance of the
rodent tumor findings. This example also
demonstrates the value ofgenetic analysis of
tumor tissues from 2-year rodent carcino-
genicity studies when there is information
from transgenic models or other sources sug-
gesting a specific carcinogenic mechanism
that can be appropriately evaluated.
In a second example of the potential
value oftransgenic models, a low incidence
ofhepatoblastoma, a rare liver tumor type
in mice that also occurs in children, was
found in a U.S. NTP mouse carcinogenicity
study of methylphenidate. This finding
resulted in a notification letter to physicians.
To further evaluate the carcinogenic mech-
anisms associated with this finding, the
suitability ofthe mouse for human extra-
polation, and the margin of safety of
methylphenidate, a p53-deficient mouse
study and a neonatal mouse study were car-
ried out in addition to comparative metabo-
lism and pharmacokinetic studies. No
evidence of a carcinogenic response was
observed in these studies, which contributed
to theweight ofevidence that suggested that
the riskto humans is minimal.
Protooncogenes can be activated by
processes such as point mutations, gene
amplification, chromosomal translocation,
and retroviral activation. Cellular onco-
gene products can be nuclear proteins
(e.g., myc), cell membrane proteins (e.g.,
ras), growth factors (e.g., sis), or growth
factor receptors (38). Major ras oncogenes
include the Harvey (Ha-ras) associated
with human epithelial tumors and rodent
tumors, the Kirsten (Ki-ras) linked to mes-
enchymal tumors, and the neuroblastoma
(N-ras) (51-53). Ras oncogenes represent
a large family of related genes linked to
cell proliferation and known to function
in various human and animal cancers. In
mice, ras mutations are found in sponta-
neous tumors and chemically induced
tumors. The type and frequency of ras
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mutations in chemically induced tumors
often differs from the ras mutations
observed in spontaneous tumors (40,54).
Promising in vivo transgenic rodent mod-
els employing ras oncogenes include the
TG.AC v-Ha-ras oncogene-based mouse
model (15,47) and the human c-Ha-ras
transgene-based mouse model (55,56). A
transgenic mouse model incorporating
the human c-Ha-ras gene is under exten-
sive evaluation in Japan and preliminary
results indicate that it can identify trans-
species genotoxic carcinogens and may
also detect nongenotoxic carcinogens
(Table 1) (56).
The xeroderma pigmentosum (XPA)-
deficient mouse is another transgenic model
currently being characterized. In humans
the XPA gene is involved in DNA nucleo-
tide excision repair and an XPA-gene defi-
cient mouse model has been developed
(57). Mutation or deletion of the XPA
gene is associated with enhanced ultraviolet
light in B frequency (UV-B)-induced skin
tumors and may also be associated with an
increased incidence ofa wide range ofsys-
temic tumors in humans (58). Transgenic
XPA-deficient mice are analogous to XPA-
deficient humans and are hypersensitive to
UV-B-induced skin tumors and also appear
sensitive to chemically induced tumors.
Although promising, the human c-Ha-ras
transgenic mouse model and XPA-deficient
mouse model have not yet been applied in a
regulatory setting.
In the TG.AC transgenic mouse
carcinogenicity model, the test compound is
topically applied to the shaved skin ofmice
daily for 20 to 26 weeks and skin papillomas
are produced in response to a carcinogen.
The skin ofthe mice in this model behaves
in a manner analogous to genetically preini-
tiated skin (59). The TG.AC model is
believed to be sensitive to both genotoxic
and nongenotoxic carcinogens (15,47) and
may be particularly well suited for the car-
cinogenicity testing oftopically applied and
dermal products. It may also have applica-
tion for assessing photococarcinogenicity,
although the utility ofthis application has
not yet been adequatelyevaluated.
The class 1 IARC carcinogen benzene
and the dass 2A IARC carcinogen 1,3-buta-
diene have been used as example compounds
to support the utility of standard 2-year
mouse carcinogenicity studies for risk assess-
ment. Carcinogens are classified by IARC
on the basis ofthe strength ofhuman, ani-
mal, and mechanistic evidence supporting
potential human carcinogenic risk. For
IARC class 1 compounds there is sufficient
Table 1. Identification of transspecies-positive compoundsa or known, probable, or possible human carcinogens
(IARC groups 1, 2A, or2B)bytransgenic mouse models.
Transgenic assayresultsb
Compound TG.AC mouse p53-deficient mouse RasH2 mouse
Sodium arsenitec
IARC group 1 human carcinogen
Negative rat and mouse studies
Nonmutagenic
Benzene
IARC group 1 human carcinogen
Nonmutagenic; genotoxic
p-Cresidine
IARC group 2B possible human carcinogen
Mutagenic; weakly genotoxic
1-Chloro-2-methylpropene
Mutagenic
Cyclophosphamide
IARC group 1 human carcinogen
Nonmutagenic
N-N-Diethyinitrosamine
Mutagenic
7,12-Dimethylbenz[a]anthracene
Mutagenic
Estradiol
IARC group 1 human carcinogen
Nonmutagenic
Ethyl acrylate
Nonmutagenic; genotoxic
Ethylene thiourea
Nonmutagenic
N-Methyl-N-nitro-N-nitrosoguanidine
Mutagenic
N-Methyl-N-nitrosourea
Mutagenic
Methylazoxymethanol
Mutagenic
Mirex
IARC group 2B possible human carcinogen
Nonmutagenic; nongenotoxic
4-Nitroquinoline-1-oxide
Mutagenic
Phenolphthaleind
Nonmutagenic; weakly genotoxic
Urethanec
IARC group 2B possible human carcinogen
Mutagenic
Vinyl carbamate
Mutagenic
Vinyl-i-cyclohexene diepoxide
Mutagenic; genotoxic
Positive NT NT
Positive
Positive
Positive
NT
NT
Positive
Positive
Negative
NT
NT
NT
NT
Positive
NT
NT
Positive
NT
NT
Positive NT
Positive NT
NT NT
NT
NT
Positive
Positive
NT
NT
NT
NT
NT
NT
NT
NT
NT
NT
NT
NT
Positive
Positive
Positive
Positive
NT
Positive
Positive
NT
NT
NT
NT
Positive
Positive
NT
Abbreviations: Genotoxic, findings generally related to clastogenicity; mutagenic, positive in vitro mutagenicity
tests (e.g., Ames/Salmonella test); NT, not tested or test results not available. "Four-cell compounds are those
that were tested in 2-year rat and mouse carcinogenicity studies and found to produce tumors in male and female
rats and mice. bData from Tennant et al. (15,47) and Yamamoto et al. (56). cTennant RW, personal communication.
dData from Dunnick et al. (49).
human evidence that the compound is car-
cinogenic. Compounds considered probable
human carcinogens are classified in IARC
2A and those considered possibly human
carcinogens are classified in 2B. Benzene,
which is carcinogenic in a 2-year mouse
study and negative in a 2-year rat study, was
positive in the TG.AC transgenic mouse and
the p53-deficient mouse (Table 1) (15).
1,3-Butadiene is genotoxic and carcinogenic
in the 2-year mouse assay. Therefore it is
likely that this substance would be positive
in thep53-deficient mouse, which is partic-
ularly sensitive to genotoxic compounds.
Other mouse-only carcinogens in the U.S.
NTP database such as chloroethane and
nitrofurantoin are genotoxic and contain
structural alerts for mutagenicity that
make them also likely to be positive in the
transgenic mouse models discussed above.
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In U.S. NTP/National Institute of
Environmental Health Sciences (NIEHS)
studies oftheTG.AC mouse, which used 26
compounds tested in 2-year rat and mouse
studies representing 0-, 1-, 2-, and 4-study
cell-positive compounds (study cells = rat,
mouse, male, female), there was concor-
dance between the TG.AC mouse and the
results of2-year bioassays. Essentially all of
the 4-cell positive compounds (transspecies
in 2-year studies) were positive in the
TG.AC transgenic mouse (Table 1). The
IARC 2B compound Mirex is positive in a
2-year rat study (mouse not tested) and the
TG.AC mouse and the IARC 2B carcino-
genp-cresidine is positive in 2-year rat and
mouse studies and also in the TG.AC and
p53-deficient mouse (15,47).
The selection ofan alternative carcino-
genicity study is expected to bescientifically
justified and should include how the study
can contribute additional mechanistic
information that may be useful for inter-
species extrapolation and the weight ofevi-
dence assessment ofcarcinogenic potential.
Issues related to the appropriateness ofthe
model, such as route ofadministration,
operational characteristics of the model,
level ofcharacterization and degree ofexpe-
rience with the model and any relevant tox-
icologic issues associated with the particular
pharmaceutical (e.g., genotoxicity) should
be addressed. This approach would not sig-
nificantly reduce-and may even
enhance-the weight ofevidence available
for assessing potential human carcinogenic
risk. Alternatively, a sponsor may conduct a
second 2-year rodent carcinogenicitystudy.
In the United States all proposals for the
use ofany alternative model are reviewed by
the U.S. FDA Center for Drug Evaluation
Carcinogenicity Assessment Committee
(CAC) prior to their initiation when
requested by the sponsor. The CAC reviews
the justification for the use ofa particular
model, the appropriateness ofthe model,
protocol design, and dosing and offers con-
currence. Concurrence on the acceptability
ofalternative studies can be granted only
when they are formally reviewed and
approved bythe CAC.
Interspecies E olation
Both human and animal metabolism and
pharmacokinetic information are avail-
able for human pharmaceuticals and are
critical components ofthe risk-assessment
process for both conventional rodent
studies and transgenic studies. In consid-
ering the results of 2-year rat and mouse
studies or transgenic rodent studies,
emphasis is placed on findings from the
rodent model that best approximate
human metabolic and pharmacokinetic
parameters. This approach was not possi-
ble until the relatively recent advent of
improved chemical analytical methods for
measuring the concentration ofdrug and
major metabolites in the blood ofhumans
and experimental animals. Comparative
pharmacokinetic and metabolism informa-
tion is also important for dose and test
model selection for carcinogenicity studies.
An evaluation of the relative systemic
exposures ofdrugs tested at the maximum
tolerated dose compared to human sys-
temic exposure at the therapeutic dose
indicated that the comparison ofdose as a
function ofbody weight generally signifi-
cantly overestimates the actual relative sys-
temic exposure ofthe test animal by 6- to
10-fold. For the estimation ofcomparative
systemic exposure, dose expressed as a
function ofbody surface area (mg/mi2) is
superior to dose expressed as body weight
(mg/kg) (37). The ratio ofthe plasma area
under the concentration-time curve for
parent drug and major metabolites in
rodents and humans is used to estimate the
relative systemic exposure ofhuman phar-
maceuticals ("Principal Elements of the
Weight-of-evidence Assessment ofCarcino-
genic Potential"). These approaches are
applied to rodents in 2-year carcinogenicity
studies and transgenic animals as was the
case for phenolphthalein.
Validation ofCarcinogenicity
Bioassays
For regulatory application it is important to
use bioassays that have been sufficiently
characterized. In adiscussion ofthe applica-
tion oftransgenic rodents in carcinogenicity
testing, it is necessary to objectively con-
sider the relative strengths and deficiencies
oftransgenic models in the context ofthe
strengths and deficiencies ofthe standard
2-year rodent carcinogenicity study. The
acceptability ofthe 2-year rodent carcino-
genicity study was based on the reasonable
assumption ofa relationship between a bio-
logical outcome in animals (neoplasia) and
potential human carcinogenic risk. Study
protocols evolved over time until a rela-
tively standard protocol developed, influ-
enced by practical considerations of
statistical power, assay sensitivity, and eco-
nomic and resource considerations. The
current study gained acceptance by the sci-
entific and regulatory community after
accumulation ofa sufficient body ofexperi-
ence and demonstrated ability to identify
compounds reasonably expected to be
carcinogens based on human and other
data. Regulatory agencies began to apply
the results ofrodent carcinogenicity studies
on the basis ofrelatively limited experience
with these assays. Although concern has
been raised about the application of trans-
genic models for quantitative risk assess-
ment, the 2-year rodent carcinogenicity
study was originally intended to be a quali-
tative screen for potential carcinogens and
may be poorly suited for quantitative risk
assessment (60).
Results oftransgenic and 2-year studies
will not always agree, especially for weaker
(single species) carcinogens associated with
species-specific mechanisms that may be less
significant for human extrapolation. Lack of
concordance between methods can also be
attributable to spurious findings related to
assay variability. In the assessment ofpoten-
tial human carcinogenic risk based on
animal studies, first priority should be given
to transspecies carcinogens that maybe more
likely to represent human risk. A critical
basic parameter for acceptability ofany car-
cinogenicity test should be the test's demon-
strated ability to detect known human
carcinogens. There are relatively few
(approximately 21) pharmaceuticals identi-
fied as group 1 human carcinogens by
IARC. The relatively small number of
known human carcinogens may be due
partly to the limitations ofepidemiologic
approaches for identifying cancer-causing
agents. Compounds that are negative in a
2-year rat and mouse study are considered
noncarcinogenic, although factors such as
thestatistical powerofthebioassay, choice of
rodent strain, species, or route ofadministra-
tion (61), or the extent ofexposure achieved
can influence the outcome. In addition it is
essentially impossible to demonstrate that
compounds that are negative in 2-year
studies are noncarcinogenic in humans.
Pharmaceuticals evaluated by IARC
and considered human carcinogens are
mainly genotoxic substances, immunosup-
pressants, or hormonal compounds. Most
ofthe nonhormonal organic compounds
are mutagens and most ofthose tested in
two rodent species are transspecies carcino-
gens (25). It often is stated in support of
rodent carcinogenicity studies that all
known human carcinogens are rodent car-
cinogens; however, it also should be stated
that many ofthese compounds were not
identified in a standard 2-year rodent car-
cinogenicity protocol. Approximately half
the IARC group 1, 2A, and 2B human
carcinogens with animal studies were tested
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by the intravenous or intraperitoneal route
for less than 2 years and in a variety of
rodent strains and study protocols (31,62).
The positive findings of these studies are
considered valid, but equivalent negative
studies generally would not be considered
adequate evidence of no carcinogenic
potential. Although many of the IARC
group 1 and 2 compounds were not tested
in standard 2-year rodent study protocols,
most are expected to be positive in the 2-
year rodent bioassay based on their geno-
toxicity and carcinogenic potency in
nonstandard tests. A similar case can be
made for transgenic rodent carcinogenicity
models and it is expected that most ofthe
IARC group 1 and 2 compounds will be
positive in many of the transgenic rodent
models currently under consideration.
Evaluation of new approaches for
assessing carcinogenic potential must be
put into proper perspective. General crite-
ria for validation of toxicology assays
endorsed by the NIEHS Interagency
Coordinating Committee for the Validation
ofAlternative Methods include assessment
ofthe repeatability and reproducibility of
the method at multiple laboratory sites.
False positive and false negative rates
should be evaluated using appropriate
reference compounds in a coded blinded
fashion (63). The current 2-year rodent
carcinogenicity study was never validated
in this manner and there is limited evi-
dence supporting the repeatability and
reproducibility ofthe results ofthe current
rodent carcinogenicity study. Two-year
rodent carcinogenicity studies for pharma-
ceuticals rarely are repeated because oftheir
considerable cost in time and resources.
When they are repeated it is generally
because offailure ofthe original study or
protocol deficiencies and therefore the
results are rarely comparable because of
protocol differences between studies (e.g.,
dose or strain differences). The repro-
ducibility ofcontrol findings in the same
study, however, can be estimated in car-
cinogenicity studies that incorporated a
protocol with separate duplicate control
groups. The U.S. NTP compiled and ana-
lyzed the results ofcarcinogenicitystudies of
18 dyes conducted by three trade associa-
tions in the same strain and source ofrats
and mice and using aprotocol that induded
separate duplicate control groups. In 12 of
18 ofthe studies, statistically significant dif-
ferences were found in a comparison ofthe
tumor findings in otherwise identical con-
trol groups (64). These findings suggest that
2-year rodent carcinogenicity studies may
have poor reproducibility because of
relatively high levels ofvariability in the
spontaneous tumor incidence rate within
studies. This supports the need for a sec-
ond species carcinogenicity study as a con-
firmatory study and is in agreement with
our experience with pharmaceutical car-
cinogenicity studies using dual identical
controls. An increasing number ofcarcino-
genicity studies for pharmaceuticals incor-
porate two identical but separately housed
and analyzed control groups to assess varia-
tions in the spontaneous tumor incidence
ratewithin a study.
Genetically inbred rodent strains are
used in 2-year rodent carcinogenicity
bioassays to minimize variability in tumor
responses attributable to genetic differ-
ences. Rodent strains currently used in car-
cinogenicity studies were not selected on
the basis oftheir suitability as human sur-
rogates but for pragmatic reasons such as
reasonable sensitivity to carcinogens and
acceptable spontaneous tumor rate, life-
span, and animal size. The large accumu-
lated historical record and experience with
currently used rodent strains is a major rea-
son for their continued use, although this
has also retarded development ofimproved
rodent strains. Although inbred strains are
used in 2-year studies to reduce genetic
diversity and variability, genetic drift is still
a concern. For many rodent strains this has
resulted in progressively larger, more obese
animals with higher spontaneous tumor
rates and reduced lifespans. This genetic
drift has compromised assay sensitivity and
the usefulness of some rodent strains in
carcinogenicity testing and has diminished
the value ofthe historical tumor record for
these strains (65-69).
The 2-year rodent carcinogenicity study
represents a pragmatic compromise, balanc-
ing factors such as test animal sensitivity,
spontaneous tumor rate, lifespan, and cost.
The relative sensitivity of most rodent
strains commonly used in 2-year carcino-
genicity studies has not been fully evaluated
by using identical studyprotocols and a ref-
erence set ofknown human carcinogens.
Positive controls ofknown carcinogens are
not commonly used in the standard 2-year
rodent carcinogenicity study protocols but
are the rule in transgenic studies. Evidence
suggests that there are similarities and
significant variations among different
rodent strains in their sensitivities to vari-
ous carcinogens and differences in the
nature and incidence of spontaneous
tumors (70-78). Many ofthese differences
may be due to species- and strain-related
(genetic) differences in metabolism and
pharmacokinetics. A wide variability in
spontaneous tumor incidence can also
occur within a rodent strain (79,80). In
addition it is now apparent that uncon-
trolled adlibitum feeding and body weight
in rodent carcinogenicity studies has been
an uncontrolled variable that significantly
influenced the sensitivity ofthe bioassay to
carcinogens (81). The tumorigenic response
to a potent carcinogen such as aflatoxin can
be significantly altered by varying the
caloric intake and body weight ofrodents
(82). Assay sensitivity is equally important
in the characterization oftransgenic rodent
models. In transgenic study protocols cur-
rendy under evaluation, a reference carcino-
gen at one or two dose levels is used in
addition to untreated and vehicle controls
to help gauge the sensitivity ofthe model
and variations in sensitivity due to protocol
or other interlaboratory studydifferences.
The sensitivity and variability oftrans-
genic rodent carcinogenicity models should
be evaluated in the context of the known
variability in sensitivity to carcinogens and
variability in spontaneous tumor responses
of rodent strains used in standard 2-year
carcinogenicity studies. In practice, there is
flexibility in the choice of rodent test
strains for 2-year carcinogenicity studies
and the choice generally is left to the indi-
vidual study director. Similar flexibility can
be applied to transgenic rodent models if
the transgenic model chosen is scientifically
justified and contributes to the evaluation
ofhuman safety.
In part because ofthe relatively high
(75%) concordance in tumorfindings in rat
and mouse 2-year carcinogenicity studies,
the degree ofexperience and characteriza-
tion necessary for the regulatory application
ofa new carcinogenicity test model to be
used as a complementary study in conjunc-
tion with a single traditional 2-year rodent
study could be less extensive than would be
expected for a replacement ofboth 2-year
rodent carcinogenicity studies. To encour-
age innovation, new emerging methods
should not necessarily be expected to attain
unrealistic levels ofvalidation-levels that
were never attained by current 2-year car-
cinogenicity studies-before they are con-
sidered for regulatory application. The
extent ofvalidation required for appli-
cation of new approaches should be con-
sidered in the context of the degree of
validation available for the current 2-year
rodent carcinogenicity study. It should be
noted that the ICH guidance on carcino-
genicity testing has resulted in increased
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interest in the development oftransgenic
rodent carcinogenicity models, fostered by
the willingness ofinternational regulatory
agencies to consider new testing models.
Because ofthe relatively short duration of
transgenic studies, the smaller number of
animals used, and their lower cost, it is
anticipated that transgenic models will
soon be available that are more extensively
characterized than the current 2-year
rodent carcinogenicity study.
Conclusions
Transgenic rodent models represent a
different and complementary approach to
carcinogenicity testing compared to the
standard 2-year rodent study. Transgenic
models have been developed that contain
regulated transgenes, unexpressed reporter
genes, or knocked out alleles of tumor-
suppressor genes. Although transgenic
models incorporating these relatively spe-
cific genetic mechanisms may not be
responsive to all compounds that tested
positive in the 2-year mouse or rat study,
transgenic models can and have been devel-
oped that incorporate carcinogenic response
elements known to be present and func-
tioning similarly in humans. Positive find-
ings in such transgenic models can offer
valuable insights into the potential rele-
vance and applicability oftumor findings to
humans that are not readily available from
standard 2-year rodent studies. Transgenic
models incorporating human protoonco-
genes may also be the only means ofidenti-
fying carcinogens that act by specific
mechanisms not present in conventional
rodent strains. Ironically, the relative speci-
ficityoftransgenic models is viewed as a lia-
bility by some who consider the standard
2-year rodent study more widely applicable
because it does not depend on any knowl-
edge oftumorigenic mechanisms or mode
ofaction for the assessment ofhuman risk.
It must be acknowledged, however, that the
absence ofsuch knowledge has been used to
question thevalidity ofextrapolating rodent
tumor findings to humans.
In addition to their application as an
alternative to a second 2-year rodent car-
cinogenicity study, there are other circum-
stances where a transgenic model may be
warranted. There are occasions when a 2-
year rodent study must be repeated because
ofinadequate survival ofmice or rats, inade-
quate dose selection, or the need to evaluate
another route ofadministration because of
a change in the clinical indication for a
drug. In such circumstances a. transgenic
rodent model may be a possible alternative
to repeating a 2-year carcinogenicity study.
In addition the relatively short duration of
the study and the reduced numbers ofani-
mals necessary for transgenic rodent studies
compared to 2-year rodent studies enhance
their possible usefulness as carcinogenicity
screening studies for decision support early
in the drug development process or in the
compound selection phase.
Based on available information there is
sufficient experience with some in vivo
transgenic rodent carcinogenicity models
to support their application as complemen-
tary second species studies in conjunction
with a single 2-year rodent carcinogenicity
study when appropriately justified. A prop-
erly selected transgenic mouse carcino-
genicity study combined with one 2-year
rat study can also adequately identify
transspecies tumorigens, which are consid-
ered most relevant for the assessment of
human risk. This approach will stimulate
innovation and the development and appli-
cation ofmethods that mayimprove assess-
ment ofpotential human carcinogenic risk,
which in turn will benefit public health.
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